期刊文献+

二次检索

题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

年份

学科

期刊收录

期刊

作者

共找到3篇文章
< 1 >
每页显示 20 50 100
hTERT原核重组质粒的表达
1
作者 许慧霞 李一冬 +1 位作者 杨胜利 赵国强 《河南肿瘤学杂志》 2005年第3期153-155,共3页
目的本课题拟观察原核重组质粒pGEX4T1hTERT在BL21细菌中的表达,为进一步探讨以hTERT为靶点的肿瘤基因免疫治疗提供实验依据。方法IPTG诱导带有pGEX4T1hTERT质粒的BL21细菌融合蛋白的表达,取不同时间的培养物进行SDSPAGE分析,并进行薄... 目的本课题拟观察原核重组质粒pGEX4T1hTERT在BL21细菌中的表达,为进一步探讨以hTERT为靶点的肿瘤基因免疫治疗提供实验依据。方法IPTG诱导带有pGEX4T1hTERT质粒的BL21细菌融合蛋白的表达,取不同时间的培养物进行SDSPAGE分析,并进行薄层凝胶光密度扫描测定目的蛋白表达量,同时对表达产物进行Westernblot检测。结果对SDSPAGE结果分析发现,含pGEX4T1hTERT质粒的BL21细菌能够表达出63kD的融合蛋白。薄层凝胶光密度扫描测定其表达水平最高为28.4%,以IPTG诱导4h表达量最高。Westernblot检测表明该融合蛋白可被hTERT多抗识别。结论诱导pGEX4T1hTERT重组质粒,获得分子量为63kD的GSThTERT融合蛋白。用抗hTERT目的基因片段表达的相应抗原蛋白。 展开更多
关键词 端粒酶逆转录酶 重组质粒 克隆表达 肿瘤免疫基因治疗
下载PDF
KIT-negative gastrointestinal stromal tumors with a long term follow-up:A new subgroup does exist 被引量:1
2
作者 Katerina Kontogianni-Katsarou Constantina Lariou +5 位作者 Eugenia Tsompanaki Christina Vourlakou Evi Kairi-Vassilatou Costas Mastoris Georgia Pantazi Agatha Kondi-Pafiti 《World Journal of Gastroenterology》 SCIE CAS CSCD 2007年第7期1098-1102,共5页
AIM: To investigate the incidence of KIT immunohostochemical staining in (GI) stromal tumors (GISTs), and to analyze the clinical manifestations of the tumors and prognostic indicators. METHODS: We retrospective... AIM: To investigate the incidence of KIT immunohostochemical staining in (GI) stromal tumors (GISTs), and to analyze the clinical manifestations of the tumors and prognostic indicators. METHODS: We retrospectively analyzed 50 cases of previously diagnosed GISTs. Tissue samples were assessed with KIT (CDl17 antigen), CD34, SMA, desmin, S-100, NSE, PCNA, Ki-67, and BCL-2 for immunohistochemical study and pathological characteristics were analyzed for prognostic factors. RESULTS: Fifteen tumors (30%) were negative in KIT staining. A significant association was observed between gender (male patients: 14/15) and KIT-negative staining (P = 0.003).The patients's mean age was 56.6 years. Tumors developed in stomach (n = 8), small intestine (n = 5), large intestine (n = 1) and oesophagus (n = 1). The mean tumor size was 5.72 cm. The mitotic count ranged from 0-29/50 HPF (mean: 3.4) and 73% of tumors showed no necrosis. The majority of the tumors (67%) had dual or epithelioid differentiation. Tumors were classified as very low or low risk (n = 7), intermediate risk (n = 5), and high risk (n = 3) groups. Twelve (80%) patients were alive without evidence of residual tumor for an average period of 40.25 mo (12-82 too); three patients developed metastatic disease to the liver and eventually died within 2-12 mo (median survival: 8.6 too).CONCLUSION: A small subgroup of GISTs fulfils the clinical and morphological criteria of these tumors, and lacks KIT expression. These tumors predominantly developed in the stomach, being dual or epithelioid in morphology, which are classified as low risk tumors and presented a better survival status than KIT-positive tumors. The ability to diagnose GISTs still depends on immunohistochemical staining but the research should extend in gene mutations. 展开更多
关键词 Gastrointestinal stromal tumors CD 117antigen IMMUNOHISTOCHEMISTRY SURVIVAL
下载PDF
中国创新生物药的研究进展 被引量:3
3
作者 王春明 夏智星 +4 位作者 郭银银 周峰 易博 李佳 俞德超 《中国新药杂志》 CAS CSCD 北大核心 2014年第20期2406-2410,共5页
创新生物药是未来新药研发的主要方向,是中国从医药大国迈向医药强国的重要突破口。本文概述了国内已批准上市和进入临床研究的、具有自主知识产权的一类创新生物药的研究进展,重点介绍了具有里程碑意义的4个自主创新生物药,分别为肿瘤... 创新生物药是未来新药研发的主要方向,是中国从医药大国迈向医药强国的重要突破口。本文概述了国内已批准上市和进入临床研究的、具有自主知识产权的一类创新生物药的研究进展,重点介绍了具有里程碑意义的4个自主创新生物药,分别为肿瘤免疫基因治疗类药物"今又生"和"安柯瑞"以及单克隆抗体类药物"利卡汀"和融合蛋白类药物"朗沐",并在此基础上指明当前生物药创新存在的机遇和挑战,提出我们的建议。 展开更多
关键词 创新生物药 肿瘤免疫基因治疗 单克隆抗体 融合蛋白 研究进展
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部